gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2019-29-5-43-48gastro-j-420Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИNATIONAL COLLEGE OF GASTROENTEROLOGY, HEPATOLOGYВоспалительные заболевания кишечника и синдром раздраженного кишечника: сочетание двух нозологических форм или разные варианты одного заболевания?Inflammatory Bowel Diseases and Irritable Bowel Syndrome: Overlap of Two Nosological Forms or Two Variants of the Same Disease?ШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович  — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней

119991, г. Москва, ул. Погодинская, д. 1, корп. 1.

Arkady A. Sheptulin — Dr. Sci. (Med.), Prof., Department of Internal Diseases Propedeutics, Medical faculty

119991, Moscow, Pogodinskaya str. 1, building 1.

arkalshep@gmail.comВиноградскаяК. Э.VinogradskayaK. E.

Виноградская Кристина Эдуардовна — студентка лечебного факультета

119991, г. Москва, ул. Погодинская, д. 1, корп. 1.

Kristina E. Vinogradskaya — Student, General Medicine Department

119991, Moscow, Pogodinskaya str. 1, building 1.

ФГАОУ ВО «Первый Московский государственный университет им. И.М. Сеченова» (Сеченовский университет) Министерства здравоохранения Российской ФедерацииРоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation2019031220192954348Copyright © Шептулин А.А., Виноградская К.Э., 20192019Шептулин А.А., Виноградская К.Э.Sheptulin A.A., Vinogradskaya K.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/420Цель обзора

Цель обзора: проанализировать данные литературы о взаимоотношениях между воспалительными заболеваниями кишечника (ВЗК) и синдромом раздраженного кишечника (СРК).

Основные положения

Основные положения. В настоящее время в опубликованных работах представлены разные точки зрения на взаимоотношения между ВЗК и СРК. Указывается, в частности, на высокую частоту развития ВЗК на фоне СРК, нередкое сохранение СРК-подобных симптомов после достижения ремиссии ВЗК, возможность «наложения» (overlap) одного заболевания на течение другого. Отстаивается концепция о признании ВЗК и СРК разными формами одного и того же заболевания. Предложено также считать СРК-подобные жалобы у больных с ремиссией ВЗК особым заболеванием и именовать его «раздраженным воспалительным кишечным синдромом». Лечение СРК-подобных симптомов у больных ВЗК в стадии ремиссии не разработано.

Заключение

Заключение: проблема о взаимоотношениях между ВЗК и СРК имеет в настоящее время противоречивую трактовку и нуждается в дальнейшем изучении.

Aim

Aim. To review available literature data on the relationship between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

Key findings

Key findings. Current publications on IBD and IBS present different viewpoints on their relationship. Thus, researchers have noted a high incidence of IBD against the background of IBS, frequent persistence of IBS-like symptoms after achieving IBD remission, as well as the possibility of overlapping the diseases. According to literature data, IBD and IBS should be treated as different forms of the same disease. An opinion is expressed that IBS-like complaints in patients with IBD remission should be considered as a separate disease referred to as “irritated inflammatory intestinal syndrome”. Treatment of IBS-like symptoms in patients with IBD remission has thus far not been developed.

Conclusion

Conclusion. The problem of the relationship between IBD and IBS is currently controversial, thus requiring further clarification.

воспалительные заболевания кишечникасиндром раздраженного кишечникаСРКподобные симптомыinflammatory bowel diseaseirritable bowel syndromeIBS-like symptomsReferencesMearin F., Perello A., Balboa A. Irritable bowel syndrome and inflammatory bowel disease: Is there a connection? Gastroenterol. Hepatol. 2009;32(5):364–72.Mearin F., Perello A., Balboa A. Irritable bowel syndrome and inflammatory bowel disease: Is there a connection? Gastroenterol. Hepatol. 2009;32(5):364–72.Barbara G., Cremon C., Stanghellini V. Inflammatory bowel disease and irritable bowel syndrome: similarities and differences. Curr. Opin. Gastroenterol. 2014;30(4):352–8.Barbara G., Cremon C., Stanghellini V. Inflammatory bowel disease and irritable bowel syndrome: similarities and differences. Curr. Opin. Gastroenterol. 2014;30(4):352–8.Rani R.A., Ali R.A.R., Lee Y.Y. Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: piece of the puzzle are falling into place. Intest. Res. 2016;14(4):297–304.Rani R.A., Ali R.A.R., Lee Y.Y. Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: piece of the puzzle are falling into place. Intest. Res. 2016;14(4):297–304.Kiank С., Tache Y., Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious IBS: role of corticotrophin-releasing factor receptors. Brain Behave Immun. 2010;24(1):41–8.Kiank С., Tache Y., Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious IBS: role of corticotrophin-releasing factor receptors. Brain Behave Immun. 2010;24(1):41–8.Noor S.O., Ridgway K., Sсovell L. et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol. 2010;10:134.Noor S.O., Ridgway K., Sсovell L. et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol. 2010;10:134.Porter C.K., Cash B.D., Pimentel M. et al. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol. 2012;12:55. DOI: 10.1186/1471-230X-12-55Porter C.K., Cash B.D., Pimentel M. et al. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol. 2012;12:55. DOI: 10.1186/1471-230X-12-55Ishihara S., Aziz M., Oshima N. et al. Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders? Clin. J. Gastroenterol. 2009;2(1):9–16.Ishihara S., Aziz M., Oshima N. et al. Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders? Clin. J. Gastroenterol. 2009;2(1):9–16.Mearin F., Lacy B.E., Chang L. et al. Bowel disorders. In: Rome IV Functional gastrointestinal disorders — disorders of gut-brain interaction (Ed. Drossman D. et al.). Rome Foundation. 2016;967–1057.Mearin F., Lacy B.E., Chang L. et al. Bowel disorders. In: Rome IV Functional gastrointestinal disorders — disorders of gut-brain interaction (Ed. Drossman D. et al.). Rome Foundation. 2016;967–1057.Quigley E.M.M. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye. Ther Adv. Gastroenterol. 2016;9(2):199–212.Quigley E.M.M. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye. Ther Adv. Gastroenterol. 2016;9(2):199–212.Ansari R., Attari F., Razjouyan H. et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur. J. Gastroenterol. 2008;20(1):46–50.Ansari R., Attari F., Razjouyan H. et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur. J. Gastroenterol. 2008;20(1):46–50.Keohane J., O’Mahony C., O’Mahony L. et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J. Gastroenterol. 2010;105(8):1789–94.Keohane J., O’Mahony C., O’Mahony L. et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J. Gastroenterol. 2010;105(8):1789–94.Piche T., Ducrotte P., Sabate J.M. et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol. Motil. 2010;22(6):626–e174.Piche T., Ducrotte P., Sabate J.M. et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol. Motil. 2010;22(6):626–e174.Jelsnes-Jorgensen L., Bernklev T., Moum B. Calprotectin is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol. Res. Pract. 2013;620707. DOI: 10/1155/2013/620707Jelsnes-Jorgensen L., Bernklev T., Moum B. Calprotectin is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol. Res. Pract. 2013;620707. DOI: 10/1155/2013/620707Kim E.S., Cho K.B., Park K.S. et al. Predictive factors on impaired quality of life in Korean patients with inactive inflammatory bowel disease: association with functional gastrointestinal disorders and mood disorders. J. Clin. Gastroenterol. 2013;47(4):38–44.Kim E.S., Cho K.B., Park K.S. et al. Predictive factors on impaired quality of life in Korean patients with inactive inflammatory bowel disease: association with functional gastrointestinal disorders and mood disorders. J. Clin. Gastroenterol. 2013;47(4):38–44.Tomita T., Kato Y., Takimoto M. et al. Prevalence of irritable bowel syndrome-like symptoms in Japanese patients with inactive inflammatory bowel disease. J. Neurogastroenterol. Motil. 2016;22(4):661–9.Tomita T., Kato Y., Takimoto M. et al. Prevalence of irritable bowel syndrome-like symptoms in Japanese patients with inactive inflammatory bowel disease. J. Neurogastroenterol. Motil. 2016;22(4):661–9.Abdalla M., Sandler R.S., Kappelman M.D. et al. Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partner. Inflamm. Bowel Dis. 2017;23(2):325–31.Abdalla M., Sandler R.S., Kappelman M.D. et al. Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partner. Inflamm. Bowel Dis. 2017;23(2):325–31.Gracie D.J., Williams C.J., Sood R. et al. Negative effects on psychological health and quality of life of genuine irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2017;15(3):376–84.Gracie D.J., Williams C.J., Sood R. et al. Negative effects on psychological health and quality of life of genuine irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2017;15(3):376–84.Henriksen M., Holvik M.L., Jelsness-Jorgensen L.P. et al. Irritable bowel-like symptoms in ulcerative colitis are as common in patients in deep remission as in inflammation: results from a population-based study [the IBSEN study]. J. Crohns Cilitis. 2018;12(4):389–93.Henriksen M., Holvik M.L., Jelsness-Jorgensen L.P. et al. Irritable bowel-like symptoms in ulcerative colitis are as common in patients in deep remission as in inflammation: results from a population-based study [the IBSEN study]. J. Crohns Cilitis. 2018;12(4):389–93.Hoekman D.R., Zeevenhooven, D’Haens G.R., Benninga M.A. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission. Eur. J. Gastroenterol. Hepatol. 2017;29(9):1086–90.Hoekman D.R., Zeevenhooven, D’Haens G.R., Benninga M.A. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission. Eur. J. Gastroenterol. Hepatol. 2017;29(9):1086–90.Perera L.P., Radigan M., Guilday C. et al. Presence of irritable bowel syndrome in quiescent inflammatory bowel disease is associated with high rate of anxiety and depression. Dig. Dis. Sci. 2019. doi: 10.1007/s10620-019-06488-8.Perera L.P., Radigan M., Guilday C. et al. Presence of irritable bowel syndrome in quiescent inflammatory bowel disease is associated with high rate of anxiety and depression. Dig. Dis. Sci. 2019. doi: 10.1007/s10620-019-06488-8.Halpin S.J., Ford A.C. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol. 2012;107(10):1474–82.Halpin S.J., Ford A.C. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol. 2012;107(10):1474–82.Berrill J.W., Green J.T., Hood K., Campbell A.R. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment. Pharmacol. Ther. 2013;38(1):44–51.Berrill J.W., Green J.T., Hood K., Campbell A.R. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment. Pharmacol. Ther. 2013;38(1):44–51.Погромов А.П., Тащян О.В., Мнацаканян М.Г., Дюкова Г.М. Спорные вопросы патогенеза и диагностики синдрома раздраженного кишечника и воспалительных заболеваний кишечника с СРК-подобными симптомами. Клин мед 2016;94(10):77–82. [Pogromov A.P., Tashchyan O.V., Mnatsakanyan M.G., Dyukova G.M. Controversial issues in the pathogenesis and diagnosis of irritable bowel syndrome and inflammatory bowel disease with IBSlike symptoms. Clin. Med. 2016;94 (10):77–82 (In Rus.)].Погромов А.П., Тащян О.В., Мнацаканян М.Г., Дюкова Г.М. Спорные вопросы патогенеза и диагностики синдрома раздраженного кишечника и воспалительных заболеваний кишечника с СРК-подобными симптомами. Клин мед 2016;94(10):77–82. [Pogromov A.P., Tashchyan O.V., Mnatsakanyan M.G., Dyukova G.M. Controversial issues in the pathogenesis and diagnosis of irritable bowel syndrome and inflammatory bowel disease with IBSlike symptoms. Clin. Med. 2016;94 (10):77–82 (In Rus.)].Bassotti G., Villanacci V., Castellani D. et al. Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission. Eur J Gastroenterol Hepatol 2006;18(5):507–10.Bassotti G., Villanacci V., Castellani D. et al. Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission. Eur J Gastroenterol Hepatol 2006;18(5):507–10.Faure C., Giguere L. Functional gastrointestinal disorders and visceral hypersensitivity in children and adolescents suffering from Crohn’s disease. Inflamm. Bowel Dis. 2008;14(11):1569–74.Faure C., Giguere L. Functional gastrointestinal disorders and visceral hypersensitivity in children and adolescents suffering from Crohn’s disease. Inflamm. Bowel Dis. 2008;14(11):1569–74.Van Hoboken E.A., Thijssen A.Y., Verhaaren R. et al. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand. J. Gastroenterol. 2011;46(7–8):981–7.Van Hoboken E.A., Thijssen A.Y., Verhaaren R. et al. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand. J. Gastroenterol. 2011;46(7–8):981–7.Akbar A., Yiangou Y., Facer P. et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with and without abdominal pain. Gut. 2010;(59):767–74.Akbar A., Yiangou Y., Facer P. et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with and without abdominal pain. Gut. 2010;(59):767–74.Gecse K., Roka R., Sera T. et al. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion. 2012;85(1):40–6.Gecse K., Roka R., Sera T. et al. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion. 2012;85(1):40–6.Bercik P., Verdu E.F., Collins S.M. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol. Clin. North. Am. 2005;34(2):235–45.Bercik P., Verdu E.F., Collins S.M. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol. Clin. North. Am. 2005;34(2):235–45.Vivinus-Nebot M., Frin-Mathy G., Bziueche H. et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low grade inflammation. Gut. 2014;63(5):744–52.Vivinus-Nebot M., Frin-Mathy G., Bziueche H. et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low grade inflammation. Gut. 2014;63(5):744–52.Bafutto M., Almeida J.R., Leite N.V. et al. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardi. Arq. Gastroenterol. 2013;50(4):304–9.Bafutto M., Almeida J.R., Leite N.V. et al. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardi. Arq. Gastroenterol. 2013;50(4):304–9.Barbara G., Cremin C., Annese V. et al. Randomised controlled trial of mesalazine in IBS. Gut. 2016;65(1):62–90.Barbara G., Cremin C., Annese V. et al. Randomised controlled trial of mesalazine in IBS. Gut. 2016;65(1):62–90.Lam C., Tan W., Leighton M. et al. A mechanistic multicentre, parallel group, randomized placebo-controlled trial of mesalazine for the treatment of IBS with diarrhea (IBSD). Gut. 2016;65(1):91–9.Lam C., Tan W., Leighton M. et al. A mechanistic multicentre, parallel group, randomized placebo-controlled trial of mesalazine for the treatment of IBS with diarrhea (IBSD). Gut. 2016;65(1):91–9.Spiller R.C. Overlap between irritable bowel syndrome and inflammatory bowel disease. Dig. Dis. 2009;27(suppl.1):48–54.Spiller R.C. Overlap between irritable bowel syndrome and inflammatory bowel disease. Dig. Dis. 2009;27(suppl.1):48–54.Long M.D., Drossman D.A. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy. Am. J. Gastroenterol. 2010;105(8):1796–8.Long M.D., Drossman D.A. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy. Am. J. Gastroenterol. 2010;105(8):1796–8.Spiller R., Мajor G. IBS and IBD — separate entities or on a spectrum? Nat. Rev. Gastroenterol. Hepatol. 2016;13(10):613–21.Spiller R., Мajor G. IBS and IBD — separate entities or on a spectrum? Nat. Rev. Gastroenterol. Hepatol. 2016;13(10):613–21.Meng J., Agrawal A., Whorwell P.J. Refractory inflammatory bowel disease — could it be an irritable bowel? Nat. Rev. Gastroenterol. Hepatol. 2013;10(1):58–61.Meng J., Agrawal A., Whorwell P.J. Refractory inflammatory bowel disease — could it be an irritable bowel? Nat. Rev. Gastroenterol. Hepatol. 2013;10(1):58–61.Oh J.H. Irritable inflammatory bowel syndrome as a distinct disease entity. J. Neurogastroenterol. Motil. 2016;22(4):545–6.Oh J.H. Irritable inflammatory bowel syndrome as a distinct disease entity. J. Neurogastroenterol. Motil. 2016;22(4):545–6.Gearry R.B., Irving P.M., Barrett J.S. et al. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAP) improves abdominal symptoms in patients with inflammatory bowel disease — a pilot study. J. Crohns Colitis. 2009;3(1):8–14.Gearry R.B., Irving P.M., Barrett J.S. et al. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAP) improves abdominal symptoms in patients with inflammatory bowel disease — a pilot study. J. Crohns Colitis. 2009;3(1):8–14.Iskandar H.N., Cassell B., Canuri N. et al. Tricyclic antidepressants for management of irritable bowel syndrome and inflammatory bowel disease. J. Clin. Gastroenterol. 2014;48:423–9.Iskandar H.N., Cassell B., Canuri N. et al. Tricyclic antidepressants for management of irritable bowel syndrome and inflammatory bowel disease. J. Clin. Gastroenterol. 2014;48:423–9.Piche T., Pishvaie D., Torouvaziam D. et al. Osteopathy decreases the severity of IBS-like symptoms associated with Crohn’s disease in patients in remission. Eur. J. Gastroenterol. Hepatol. 2014;26(12):1392–8.Piche T., Pishvaie D., Torouvaziam D. et al. Osteopathy decreases the severity of IBS-like symptoms associated with Crohn’s disease in patients in remission. Eur. J. Gastroenterol. Hepatol. 2014;26(12):1392–8.Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., Белоусова Е.А., Бениашвили А.Г., Васильев С.В., Головенко А.О., Григорьев Е.Г., Костенко Н.В., Лапина Т.Л., Лоранская И.Д., ЛяшенкоО.С., МаевИ.В., ПолуэктоваЕ.А., РумянцевВ.Г., Тимербулатов В.М., Трухманов А.С., Фоменко О.Ю., Халиф И.Л., Чашкова Е.Ю., Шептулин А.А., Шифрин О.С., Яновой В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2017;27(5):76–93. [Ivashkin V.T., Shelygin Yu.A., Baranskaya Ye.K., Belousova Ye.A., Beniashvili A.G., Vasilyev S.V., Golovenko A.O., Golovenko O.V., Grigoryev Ye.G., Kostenko N.V., Lapina T.L., Loranskaya I.D., Lyashenko O.S., Mayev I.V., Poluektova Ye.A., Rumyantsev V.G., Timerbulatov V.M., Trukhmanov A.S., Fomenko O.Yu., Khalif I.L., Chashkova E.Yu., Sheptulin A.A., Shifrin O.S., Yanovoy V.V. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Ross. z gastroenterol. gepatol. koloproktol. 2017;27(5):76–93 (In Rus.)]. DOI: 10.22416/1382-4376-2017-27-5-76-93Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., Белоусова Е.А., Бениашвили А.Г., Васильев С.В., Головенко А.О., Григорьев Е.Г., Костенко Н.В., Лапина Т.Л., Лоранская И.Д., ЛяшенкоО.С., МаевИ.В., ПолуэктоваЕ.А., РумянцевВ.Г., Тимербулатов В.М., Трухманов А.С., Фоменко О.Ю., Халиф И.Л., Чашкова Е.Ю., Шептулин А.А., Шифрин О.С., Яновой В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2017;27(5):76–93. [Ivashkin V.T., Shelygin Yu.A., Baranskaya Ye.K., Belousova Ye.A., Beniashvili A.G., Vasilyev S.V., Golovenko A.O., Golovenko O.V., Grigoryev Ye.G., Kostenko N.V., Lapina T.L., Loranskaya I.D., Lyashenko O.S., Mayev I.V., Poluektova Ye.A., Rumyantsev V.G., Timerbulatov V.M., Trukhmanov A.S., Fomenko O.Yu., Khalif I.L., Chashkova E.Yu., Sheptulin A.A., Shifrin O.S., Yanovoy V.V. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Ross. z gastroenterol. gepatol. koloproktol. 2017;27(5):76–93 (In Rus.)]. DOI: 10.22416/1382-4376-2017-27-5-76-93Camilleri M. Managing symptoms of irritable bowel symptoms in patients with inflammatory bowel syndrome. Gut. 2011;60(4):425–8.Camilleri M. Managing symptoms of irritable bowel symptoms in patients with inflammatory bowel syndrome. Gut. 2011;60(4):425–8.

The authors declare that there are no conflicts of interest present.